A phase i study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 959-970

  Ricart, Alejandro D ^a   Ashton, Edward A ^b   Cooney, Matthew M ^c   Sarantopoulos, John ^a   Brell, Joanna M ^d   Feldman, Maria A ^e   Ruby, Kale E ^e   Matsuda, Kazuko ^e   Munsey, Mark S ^e   Medina, Gerardo ^a   Zambito, Angela ^c   Tolcher, Anthony W ^a   Remick, Scot C ^c  

^a CTRC Institute for Drug Development   (United States)

^b VirtualScopics LLC   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MediciNova Inc   (United States)

Author keywords

MN 029; Phase I; Vascular disrupting agent

Indexed keywords

DENIBULIN; DRUG METABOLITE; MN 021; MN 022; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CARCINOID; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FATIGUE; FEMALE; GASTRINOMA; HEAD AND NECK CANCER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; ST SEGMENT DEPRESSION; STOMATITIS; SYSTOLIC BLOOD PRESSURE; T WAVE INVERSION; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ISCHEMIC ATTACK; TUMOR BLOOD FLOW; URETHRA CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 80054743497     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1565-4     Document Type: Article

References (48)

1. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528: DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
2. MJ Ratain T Eisen WM Stadler, et al. 2006 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505 2512 16636341 10.1200/JCO.2005.03.6723 1:CAS:528:DC%2BD28XmtVOmtrk%3D (Pubitemid 46630627)
3. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
4. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
5. DW Siemann MC Bibby GG Dark, et al. 2005 Differentiation and definition of vascular-targeted therapies Clin Cancer Res 11 416 420 15701823 1:CAS:528:DC%2BD2MXislWgtro%3D (Pubitemid 40116863)
6. PE Thorpe 2004 Vascular targeting agents as cancer therapeutics Clin Cancer Res 10 415 427 14760060 10.1158/1078-0432.CCR-0642-03 (Pubitemid 38173977)
7. MM Cooney W van Heeckeren S Bhakta, et al. 2006 Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery Nat Clin Pract Oncol 3 682 692 17139319 10.1038/ncponc0663 1:CAS:528: DC%2BD2sXksFKrsg%3D%3D (Pubitemid 44843126)
8. PE Thorpe DJ Chaplin DC Blakey 2003 The first international conference on vascular targeting: meeting overview Cancer Res 63 1144 1147 12615734 1:CAS:528:DC%2BD3sXhs1agtLY%3D (Pubitemid 36278450)
9. GM Tozer VE Prise J Wilson, et al. 2001 Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability Cancer Res 61 6413 6422 11522635 1:CAS:528:DC%2BD3MXmsF2jsLk%3D (Pubitemid 32785286)
10. PD Davis GJ Dougherty DC Blakey, et al. 2002 ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res 62 7247 7253 12499266 1:CAS:528:DC%2BD3sXhtVyqtA%3D%3D (Pubitemid 36025246)
11. A Dowlati K Robertson M Cooney, et al. 2002 A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer Cancer Res 62 3408 3416 12067983 1:CAS:528:DC%2BD38XkslWqsbw%3D (Pubitemid 34651387)
12. SM Galbraith GJ Rustin MA Lodge, et al. 2002 Effects of 5, 6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging J Clin Oncol 20 3826 3840 12228202 10.1200/JCO.2002.09.144 1:CAS:528:DC%2BD38XntVyns7g%3D
13. SM Galbraith RJ Maxwell MA Lodge, et al. 2003 Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J Clin Oncol 21 2831 2842 12807936 10.1200/JCO.2003.05.187 1:CAS:528:DC%2BD2cXpsVKjsb8%3D (Pubitemid 46621830)
14. JM Collins 2003 Functional imaging in phase I studies: decorations or decision making? J Clin Oncol 21 2807 2809 12807933 10.1200/JCO.2003.05.100 (Pubitemid 46621827)
15. JL Evelhoch PM LoRusso Z He, et al. 2004 Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126 Clin Cancer Res 10 3650 3657 15173071 10.1158/1078-0432.CCR-03-0417 1:CAS:528:DC%2BD2cXksVKnsbo%3D (Pubitemid 38697598)
16. CS Parkins MF Dennis MR Stratford, et al. 1995 Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide Cancer Res 55 6026 6029 8521386 1:CAS:528:DyaK2MXhtVShtL7K
17. MR Horsman DW Siemann 2006 Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies Cancer Res 66 11520 11539 17178843 10.1158/0008-5472.CAN-06-2848 1:CAS:528: DC%2BD28XhtlagurrP (Pubitemid 46094158)
18. MN-029 Investigator's brochure in Medicinova Inc (2004)
19. W Shi DW Siemann 2005 Preclinical studies of the novel vascular disrupting agent MN-029 Anticancer Res 25 3899 3904 16309177 1:CAS:528:DC%2BD2MXht12itrfJ (Pubitemid 41665162)
20. R Simon B Freidlin L Rubinstein, et al. 1997 Accelerated titration designs for phase I clinical trials in oncology J Natl Cancer Inst 89 1138 1147 9262252 10.1093/jnci/89.15.1138 1:CAS:528:DyaK2sXls1WnurY%3D (Pubitemid 27337928)
21. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
22. E Ashton T McShane J Evelhoch 2005 Inter-operator variability in perfusion assessment of tumors in MRI using automated AIF detection LNCS 3749 451 458 (Pubitemid 43828282)
23. Johnson NL, Kotz S, Balakrishnan N (1994) Continuous univariate distributions. Wiley, New York, pp 127-129
24. M Leach K Brindle J Evelhoch, et al. 2005 The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br J Cancer 92 1599 1610 15870830 10.1038/sj.bjc.6602550 1:CAS:528:DC%2BD2MXjvVansbs%3D (Pubitemid 40756468)
25. J Evelhoch 1999 Key factors in the acquisition of contrast kinetic data for oncology J Magn Reson Imaging 10 254 259 10508284 10.1002/(SICI)1522- 2586(199909)10:3<254::AID-JMRI5>3.0.CO;2-9 1:STN:280:DyaK1Mvjsl2jug%3D%3D (Pubitemid 29463107)
26. GG Dark SA Hill VE Prise, et al. 1997 Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Res 57 1829 1834 9157969 1:CAS:528:DyaK2sXjtlGnsbk%3D (Pubitemid 27209705)
27. MB Jameson PI Thompson BC Baguley, et al. 2003 Clinical aspects of a phase I trial of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent Br J Cancer 88 1844 1850 12799625 10.1038/sj.bjc.6600992 1:CAS:528:DC%2BD3sXksVKjtbw%3D (Pubitemid 36829657)
28. GJ Rustin SM Galbraith H Anderson, et al. 2003 Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results J Clin Oncol 21 2815 2822 12807934 10.1200/JCO.2003.05.185 1:CAS:528: DC%2BD2cXpsVKjsLk%3D (Pubitemid 46621828)
29. LV Beerepoot SA Radema EO Witteveen, et al. 2006 Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors J Clin Oncol 24 1491 1498 16574998 10.1200/JCO.2005.02.7458 1:CAS:528:DC%2BD28XjvFyksbg%3D (Pubitemid 46638769)
30. WJ van Heeckeren S Bhakta J Ortiz, et al. 2006 Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 24 1485 1488 16574996 10.1200/JCO.2005.04.8801 (Pubitemid 46638767)
31. HL Anderson JT Yap MP Miller, et al. 2003 Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate J Clin Oncol 21 2823 2830 12807935 10.1200/JCO.2003.05.186 1:CAS:528:DC%2BD2cXpsVKjsLc%3D (Pubitemid 46621829)
32. MM Cooney T Radivoyevitch A Dowlati, et al. 2004 Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer Clin Cancer Res 10 96 100 14734457 10.1158/1078-0432.CCR-0364-3 1:CAS:528:DC%2BD2cXkvF2qsw%3D%3D (Pubitemid 38114167)
33. DJ Chaplin SA Hill 2002 The development of combretastatin A4 phosphate as a vascular targeting agent Int J Radiat Oncol Biol Phys 54 1491 1496 12459376 10.1016/S0360-3016(02)03924-X 1:CAS:528:DC%2BD38XovFKjsbo%3D (Pubitemid 35380054)
34. Y Shaked A Ciarrocchi M Franco, et al. 2006 Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 1785 1787 16990548 10.1126/science.1127592 1:CAS:528:DC%2BD28Xpsl2qs74%3D (Pubitemid 44454154)
35. P Mancuso M Colleoni A Calleri, et al. 2006 Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy Blood 108 452 459 16543470 10.1182/blood-2005-11-4570 1:CAS:528:DC%2BD28XntFeht78%3D (Pubitemid 44061341)
36. CG Willett Y Boucher E di Tomaso, et al. 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 147 14745444 10.1038/nm988 1:CAS:528: DC%2BD2cXoslKmtQ%3D%3D (Pubitemid 38524883)
37. A Solovey Y Lin P Browne, et al. 1997 Circulating activated endothelial cells in sickle cell anemia N Engl J Med 337 1584 1590 9371854 10.1056/NEJM199711273372203 1:STN:280:DyaK1c%2Fis1OqsA%3D%3D (Pubitemid 27509761)
38. LV Beerepoot N Mehra JS Vermaat, et al. 2004 Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients Ann Oncol 15 139 145 14679134 10.1093/annonc/mdh017 1:STN:280:DC%2BD3srps1Kltg%3D%3D (Pubitemid 38139616)
39. P Mancuso A Burlini G Pruneri, et al. 2001 Resting and activated endothelial cells are increased in the peripheral blood of cancer patients Blood 97 3658 3661 11369666 10.1182/blood.V97.11.3658 1:CAS:528:DC%2BD3MXktFOku7k%3D
40. S Monestiroli P Mancuso A Burlini, et al. 2001 Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma Cancer Res 61 4341 4344 11389057 1:CAS:528: DC%2BD3MXktlSqu74%3D (Pubitemid 32685756)
41. Y Shaked F Bertolini S Man, et al. 2005 Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis Cancer Cell 7 101 111 15652753 1:CAS:528:DC%2BD2MXhsVait7w%3D (Pubitemid 40126386)
42. W Shi DW Siemann 2005 Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474 In Vivo 19 1045 1050 16277020 1:CAS:528:DC%2BD2MXht1amt7fJ (Pubitemid 41631508)
43. E Ashton D Raunig C Ng, et al. 2008 Scan-rescan variability in perfusion assessment of tumors in MRI using both model and data-derived arterial input function J Magn Reson Imaging 28 791 796 18777526 10.1002/jmri.21472
44. M Rijpkema J Kaanders F Joosten, et al. 2001 Method for quantitative mapping of dynamic MRI contrast agent enhancement in human tumors J Magn Reson Imaging 14 457 463 11599071 10.1002/jmri.1207 1:STN:280:DC%2BD3MrkvFOjsw%3D%3D (Pubitemid 32906564)
45. DW Siemann DJ Chaplin PA Walicke 2009 A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) Expert Opin Investig Drugs 18 189 197 19236265 10.1517/13543780802691068 1:CAS:528:DC%2BD1MXnsVWmsg%3D%3D
46. Garon EB, Kabbinavar FF, Neidhart JA et al. (2010) Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial. J Clin Oncol 28:7s (abstr 7587)
47. Nathan PD, Judson I, Padhani A et al. (2008) A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 26 (abstr 3550)
48. AM Traynor MS Gordon D Alberti, et al. 2010 A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors Invest New Drugs 28 509 515 19434370 10.1007/s10637-009-9264-2 1:CAS:528: DC%2BC3cXmtlyhurY%3D